GARP Stocks
BSX is part of our growth-at-reasonable-price stock list, indicating it is growing while not too expensive.
BOSTON SCIENTIFIC CORP (BSX) Stock Price & Overview
NYSE:BSX • US1011371077
Current stock price
63.87 USD
-0.74 (-1.15%)
Last:
The current stock price of BSX is 63.87 USD. Today BSX is down by -1.15%. In the past month the price decreased by -9.26%. In the past year, price decreased by -32.08%.
BSX Key Statistics
52-Week Range60.59 - 109.5
Current BSX stock price positioned within its 52-week range.
1-Month Range60.59 - 71.94
Current BSX stock price positioned within its 1-month range.
- Market Cap
- 94.922B
- P/E
- 20.94
- Fwd P/E
- 18.32
- EPS (TTM)
- 3.05
- Dividend Yield
- N/A
BSX Stock Performance
Today
-1.15%
1 Week
+3.28%
1 Month
-9.26%
3 Months
-26.64%
Longer-term
6 Months -34.90%
1 Year -32.08%
2 Years -10.10%
3 Years +23.96%
5 Years +48.19%
10 Years +194.75%
BSX Stock Chart
BSX Stock Screens
BSX currently appears in the following ChartMill screener lists.
BSX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BSX. When comparing the yearly performance of all stocks, BSX is a bad performer in the overall market: 90% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
BSX Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to BSX. Both the health and profitability get an excellent rating, making BSX a very profitable company, without any liquidiy or solvency issues.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BSX Earnings
On February 4, 2026 BSX reported an EPS of 0.8 and a revenue of 5.29B. The company beat EPS expectations (1.62% surprise) and missed revenue expectations (-0.88% surprise).
Next Earnings DateApr 22, 2026
Last Earnings DateFeb 4, 2026
PeriodQ4 / 2025
EPS Reported$0.80
Revenue Reported5.286B
EPS Surprise 1.62%
Revenue Surprise -0.88%
BSX Forecast & Estimates
41 analysts have analysed BSX and the average price target is 103.74 USD. This implies a price increase of 62.43% is expected in the next year compared to the current price of 63.87.
For the next year, analysts expect an EPS growth of 14.33% and a revenue growth 10.8% for BSX
Analysts
Analysts84.88
Price Target103.74 (62.42%)
EPS Next Y14.33%
Revenue Next Year10.8%
BSX Groups
Sector & Classification
Sector
Health Care Sub-Industry
Health Care Equipment BSX Financial Highlights
Over the last trailing twelve months BSX reported a non-GAAP Earnings per Share(EPS) of 3.05. The EPS increased by 21.51% compared to the year before.
Income Statements
Revenue(TTM)20.07B
Net Income(TTM)2.90B
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.44% | ||
| ROA | 6.64% | ||
| ROE | 11.96% | ||
| Debt/Equity | 0.46 |
Chartmill High Growth Momentum
EPS Q2Q%14.29%
Sales Q2Q%15.9%
EPS 1Y (TTM)21.51%
Revenue 1Y (TTM)19.88%
BSX Ownership
Ownership
Inst Owners94.54%
Shares1.49B
Float1.48B
Ins Owners0.16%
Short Float %1.59%
Short Ratio1.37
BSX Latest News, Press Relases and Analysis
9 days ago - By: Chartmill
BSX Competitors/Peers
The largest stocks on the US markets in the "Health Care Equipment" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 16.7 | 176.478B | ||
| ISRG | INTUITIVE SURGICAL INC | 44.47 | 166.347B | ||
| SYK | STRYKER CORP | 22.29 | 130.688B | ||
| IDXX | IDEXX LABORATORIES INC | 38.7 | 46.124B | ||
| EW | EDWARDS LIFESCIENCES CORP | 25.9 | 45.085B | ||
| BDX | BECTON DICKINSON AND CO | 11.37 | 44.283B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 14.22 | 33.542B | ||
| RMD | RESMED INC | 18.44 | 33.332B | ||
| DXCM | DEXCOM INC | 24.16 | 23.684B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.13 | 18.234B | ||
| HOLX | HOLOGIC INC | 15.48 | 16.969B | ||
| PODD | INSULET CORP | 31.19 | 14.256B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BSX
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Company Info
IPO: 1992-05-19
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752 US
CEO: Michael F. Mahoney
Employees: 59000
Phone: 13026365400
BOSTON SCIENTIFIC CORP / BSX FAQ
What does BOSTON SCIENTIFIC CORP do?
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 59,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
What is the current price of BSX stock?
The current stock price of BSX is 63.87 USD. The price decreased by -1.15% in the last trading session.
What is the dividend status of BOSTON SCIENTIFIC CORP?
BSX does not pay a dividend.
How is the ChartMill rating for BOSTON SCIENTIFIC CORP?
BSX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Would investing in BOSTON SCIENTIFIC CORP be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BSX.
What is BOSTON SCIENTIFIC CORP worth?
BOSTON SCIENTIFIC CORP (BSX) has a market capitalization of 94.92B USD. This makes BSX a Large Cap stock.